<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507074</url>
  </required_header>
  <id_info>
    <org_study_id>PoznanUPhyEd no. 3</org_study_id>
    <nct_id>NCT04507074</nct_id>
  </id_info>
  <brief_title>The Effect of Traction Forces in People With Obesity Suffering From Chronic Low Back Pain</brief_title>
  <official_title>The Effect of Traction Forces on Changes in Biochemical Markers of Degeneration and Functional Parameters of the Spine in People With Obesity Suffering From Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Physical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Physical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research study is to assess the impact of traction forces on changes in&#xD;
      systemic markers concentrations of spinal structure damage in people with obesity. The&#xD;
      research group will include 40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and&#xD;
      chronic lumbar spine pain syndrome.&#xD;
&#xD;
      The control group will consist of 20 subjects with normal body weight suffering from the same&#xD;
      pain, at a similar age to the patients in the study group. Persons will be qualified for&#xD;
      examination by a specialist in internal medicine and a physiotherapist.&#xD;
&#xD;
      To assess the degree of structural damage within the intervertebral disc and adjacent&#xD;
      anatomical structures, patients will undergo magnetic resonance imaging of the lumbosacral&#xD;
      spine (MRI 1.5T, standard in 3 projections). Patients will undergo traction therapy under the&#xD;
      supervision of a physiotherapist. The application of traction forces on the traction table&#xD;
      (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with&#xD;
      a maximum strength of 30% of the patient's body weight).&#xD;
&#xD;
      Twice, before and after therapy, the following will be assessed: (1) body composition (by DXA&#xD;
      method), (2) other anthropometric indicators, (3) functional parameters of the spine:&#xD;
      mobility (electrogoniometer), muscle bioelectric signal amplitude (electromyograph), soft&#xD;
      tissue biophysical parameters (myotonometer), (4) pain threshold and intensity in the lumbar&#xD;
      region (using an algometer and validated questionnaires), (5) disability caused by pain in&#xD;
      the spine (Oswestry questionnaire), (6) blood biochemical indicators selected on the basis of&#xD;
      the latest research on biomarkers of spinal damage (for this purpose, 25ml venous blood will&#xD;
      be taken from the subjects).&#xD;
&#xD;
      Blood levels of interleukin-17, interleukin-4, interleukin-2 (IL-2), interleukin-10 (IL-10),&#xD;
      differentiating growth factor 15 (GDF-15), leptin, adipsin, chemokine CCL5 (RANTES), stem&#xD;
      cell growth factor β (SCGF-β), vascular endothelial growth factor (VEGF), neuropeptide Y, and&#xD;
      chondroitin sulfate CS846 will be determined in the blood of the subjects. It is planned to&#xD;
      assess the relationship of the studied biomarkers with the degree of disk degeneration,&#xD;
      obesity, lean and fat body mass, pain intensity, and functional indicators of the spine.&#xD;
      Patients will be asked to stop taking anti-inflammatory drugs during therapy and at least 24&#xD;
      hours prior to blood sampling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People suffering from obesity are particularly vulnerable to mechanical compression of the&#xD;
      intervertebral discs, and as a result their degeneration, hernia and pressure on the nerve&#xD;
      roots, which together cause inflammation and pain in the damaged area. This is a significant&#xD;
      public health problem due to the 100% incidence of pain syndrome among people with obesity.&#xD;
      The use of traction forces has beneficial effects on degenerated intervertebral discs, but&#xD;
      there are no studies assessing the effectiveness of the traction method in relation to a&#xD;
      group of obese people with back pain syndrome.&#xD;
&#xD;
      Beneficial biochemical changes in the blood, alleviation of pain, improvement of functional&#xD;
      parameters of the spine are expected after application of traction forces to the patients in&#xD;
      the mechanism of decompression of the destroyed and being in chronic inflammation&#xD;
      intervertebral discs. Identification of biomarkers enabling to monitor the effects of&#xD;
      therapies in patients with chronic back pain can become a contribution to change standards in&#xD;
      the diagnosis of back pain and reorientation in its treatment to real causes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-2, interleukin-4, interleukin-10, interleukin-17, RANTES, differentiating growth factor 15 (GDF-15) [pg/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-2, interleukin-4, interleukin-10, interleukin-17, RANTES, differentiating growth factor 15 (GDF-15) [pg/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stem cell growth factor β [ng/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stem cell growth factor β [ng/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leptin [ng/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leptin [ng/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adipsin [pg/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adipsin [pg/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropeptide Y [pg/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropeptide Y [pg/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Endothelial Growth Factor [pg/ml]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Endothelial Growth Factor [pg/ml]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chondroitin sulfate CS846 [ng/mL]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chondroitin sulfate CS846 [ng/mL]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging of the lumbosacral spine</measure>
    <time_frame>pre-intervention</time_frame>
    <description>MRI 1.5T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fat content [%]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>dual energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fat content [%]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>dual energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass [kg]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>dual energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass [kg]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>dual energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility of the spine</measure>
    <time_frame>pre-intervention</time_frame>
    <description>electrogoniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility of the spine</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>electrogoniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle bioelectric signal amplitude</measure>
    <time_frame>pre-intervention</time_frame>
    <description>electromyograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle bioelectric signal amplitude</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>electromyograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State of tension of erector spinae muscles [Hz]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>Natural oscillation frequency [Hz], characterizing Tone or Tension will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic stiffness of erector spinae muscles [N/m]</measure>
    <time_frame>pre-intervention</time_frame>
    <description>Biomechanical properties will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logarithmic decrement of natural oscillation, characterizing elasticity of erector spinae muscles</measure>
    <time_frame>pre-intervention</time_frame>
    <description>Biomechanical properties will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State of tension of erector spinae muscles [Hz]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>Natural oscillation frequency [Hz], characterizing Tone or Tension will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic stiffness of erector spinae muscles [N/m]</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>Biomechanical properties will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logarithmic decrement of natural oscillation, characterizing elasticity of erector spinae muscles</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>Biomechanical properties will be assessed with myotonometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain threshold</measure>
    <time_frame>pre-intervention</time_frame>
    <description>algometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain threshold</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>algometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity: questionnaire</measure>
    <time_frame>pre-intervention</time_frame>
    <description>visual analogue scale (VAS) pain intensity questionare (reporting a score on a 10-point scale, the minimum (0) means no pain and the maximum (10) means a worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity: questionnaire</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>visual analogue scale (VAS) pain intensity questionare (reporting a score on a 10-point scale, the minimum (0) means no pain and the maximum (10) means a worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability caused by pain in the spine</measure>
    <time_frame>pre-intervention</time_frame>
    <description>Oswestry questionnaire. When completing the questionnaire, the subject answers questions concerning: pain intensity, independence, lifting objects, walking, sitting, standing, sleeping, social life, sexual activity and traveling. The answers to the questions help to classify how limited the functioning of the patient is while performing certain activities. Responses are graded from 0 to 5. The overall score is given on a 0-50 point scale, where the higher the score, the greater the disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability caused by pain in the spine</measure>
    <time_frame>48 hours after the intervention</time_frame>
    <description>Oswestry questionnaire. When completing the questionnaire, the subject answers questions concerning: pain intensity, independence, lifting objects, walking, sitting, standing, sleeping, social life, sexual activity and traveling. The answers to the questions help to classify how limited the functioning of the patient is while performing certain activities. Responses are graded from 0 to 5. The overall score is given on a 0-50 point scale, where the higher the score, the greater the disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Patients With Obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-Weight Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lumbar traction therapy</intervention_name>
    <description>The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).</description>
    <arm_group_label>Normal-Weight Patients</arm_group_label>
    <arm_group_label>Patients With Obesity</arm_group_label>
    <other_name>lumbar traction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written consent to participate in the study,&#xD;
&#xD;
          2. Age: 35 - 60 years,&#xD;
&#xD;
          3. Obesity (BMI ≥ 30 kg / m2) or normal weight (BMI 18,5-29,9 kg/m2),&#xD;
&#xD;
          4. Stable body weight in the last month ± 2 kg,&#xD;
&#xD;
          5. Chronic low back pain.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary form of obesity;&#xD;
&#xD;
          2. Serious neurological defects (including large muscle losses, sensory disturbances in a&#xD;
             large area of the lower limb, occurrence of cauda equina syndrome);&#xD;
&#xD;
          3. Surgery, post-accident mechanical injuries, history of spine fractures;&#xD;
&#xD;
          4. History of rheumatic disease (RA, ankylosing spondylitis, systemic lupus);&#xD;
&#xD;
          5. Osteoporosis;&#xD;
&#xD;
          6. Pain located in a location other than the spine which is more severe than the low back&#xD;
             pain;&#xD;
&#xD;
          7. Poorly controlled type 2 diabetes;&#xD;
&#xD;
          8. Poorly controlled hypertension (mean systolic blood pressure&gt; 140mmHg and / or average&#xD;
             diastolic blood pressure&gt; 90mmHg) during the last month and / or the necessity of&#xD;
             modification of pharmacological treatment;&#xD;
&#xD;
          9. Lipid disorders requiring the introduction of pharmacological treatment in the last 3&#xD;
             months before observation or during observation;&#xD;
&#xD;
         10. Acute coronary event, unstable angina, stroke or transient cerebral ischemia in the&#xD;
             last 6 months;&#xD;
&#xD;
         11. Features of heart failure in physical examination and / or additional tests (chest&#xD;
             X-ray, echocardiography);&#xD;
&#xD;
         12. Clinically significant arrhythmias, conduction disorders, pacemaker implantation;&#xD;
&#xD;
         13. Fainting in an interview,&#xD;
&#xD;
         14. Chronic kidney disease with creatinine clearance &lt;60mL / min / 1.73m2;&#xD;
&#xD;
         15. Clinically significant liver dysfunction (transaminases exceeding 3 times the normal&#xD;
             range);&#xD;
&#xD;
         16. Acute or chronic, clinically apparent inflammatory process of the respiratory tract,&#xD;
             inflammatory processes of the genitourinary system, inflammatory process in the head&#xD;
             and neck;&#xD;
&#xD;
         17. Acute infection in the last month;&#xD;
&#xD;
         18. Cancer;&#xD;
&#xD;
         19. Alcohol abuse, drug addiction;&#xD;
&#xD;
         20. Pregnancy;&#xD;
&#xD;
         21. Uncontrolled mental illness that may falsify test results;&#xD;
&#xD;
         22. Other conditions which may pose any risk to the patient during the observation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Poznan University of Physical Education</name>
      <address>
        <city>Poznań</city>
        <zip>61-871</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Chow DHK, Yuen EMK, Xiao L, Leung MCP. Mechanical effects of traction on lumbar intervertebral discs: A magnetic resonance imaging study. Musculoskelet Sci Pract. 2017 Jun;29:78-83. doi: 10.1016/j.msksp.2017.03.007. Epub 2017 Mar 20.</citation>
    <PMID>28347933</PMID>
  </reference>
  <reference>
    <citation>Omarker K, Myers RR. Pathogenesis of sciatic pain: role of herniated nucleus pulposus and deformation of spinal nerve root and dorsal root ganglion. Pain. 1998 Nov;78(2):99-105. doi: 10.1016/S0304-3959(98)00119-5.</citation>
    <PMID>9839819</PMID>
  </reference>
  <reference>
    <citation>Maciaszek J, Skrypnik D, Ratajczak M, Stemplewski R, Osiński W, Bogdański P, Mądry E, Walkowiak J, Karolkiewicz J. Two aerobic exercise programs in management of back pain among middle-aged obese women: A randomized controlled study. Human Movement. 2016; 17(2): 72-79.</citation>
  </reference>
  <reference>
    <citation>Weber KT, Satoh S, Alipui DO, Virojanapa J, Levine M, Sison C, Quraishi S, Bloom O, Chahine NO. Exploratory study for identifying systemic biomarkers that correlate with pain response in patients with intervertebral disc disorders. Immunol Res. 2015 Dec;63(1-3):170-80. doi: 10.1007/s12026-015-8709-2.</citation>
    <PMID>26440592</PMID>
  </reference>
  <reference>
    <citation>Tarabeih N, Shalata A, Trofimov S, Kalinkovich A, Livshits G. Growth and differentiation factor 15 is a biomarker for low back pain-associated disability. Cytokine. 2019 May;117:8-14. doi: 10.1016/j.cyto.2019.01.011. Epub 2019 Feb 15.</citation>
    <PMID>30776685</PMID>
  </reference>
  <reference>
    <citation>Sowa GA, Perera S, Bechara B, Agarwal V, Boardman J, Huang W, Camacho-Soto A, Vo N, Kang J, Weiner D. Associations between serum biomarkers and pain and pain-related function in older adults with low back pain: a pilot study. J Am Geriatr Soc. 2014 Nov;62(11):2047-55. doi: 10.1111/jgs.13102. Epub 2014 Nov 3.</citation>
    <PMID>25367206</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Physical Education</investigator_affiliation>
    <investigator_full_name>Marzena Ratajczak</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>biomarkers of low back pain</keyword>
  <keyword>inflammation</keyword>
  <keyword>disk degeneration</keyword>
  <keyword>traction therapy</keyword>
  <keyword>lumbar traction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

